Abstract
The treatment of brain tumors and neurodegenerative diseases, represents an ongoing challenge. In Central Nervous System (CNS) the achievement of therapeutic concentration of chemical agents is complicated by the presence of distinct set of efflux proteins, such as ATP-Binding Cassette (ABC) transporters localized on the Blood-Brain Barrier (BBB). The activity of ABC transporters seems to be a common mechanism that underlies the poor response of CNS diseases to therapies.
The molecular characterization of Breast Cancer Resistance Protein (BCRP/ABCG2), as an ABC transporter conferring multidrug resistance (MDR), has stimulated many studies to investigate its activity on the BBB, its involvement in physiology and CNS diseases and its role in limiting the delivery of drugs in CNS.
In this review, we highlight the activity and localization of BCRP on the BBB and the action that this efflux pump has on many conventional drugs or latest generation molecules used for the treatment of CNS tumors and other neurodegenerative diseases.
Keywords: BCRP, Blood-Brain Barrier, brain tumors, multidrug resistance, neurodegenerative diseases.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Volume: 16 Issue: 7
Author(s): Anna Lisa Iorio, Martina da Ros, Ornella Fantappiè, Maurizio Lucchesi, Ludovica Facchini, Alessia Stival, Sabrina Becciani, Milena Guidi, Claudio Favre, Maurizio de Martino, Lorenzo Genitori and Iacopo Sardi
Affiliation:
Keywords: BCRP, Blood-Brain Barrier, brain tumors, multidrug resistance, neurodegenerative diseases.
Abstract: The treatment of brain tumors and neurodegenerative diseases, represents an ongoing challenge. In Central Nervous System (CNS) the achievement of therapeutic concentration of chemical agents is complicated by the presence of distinct set of efflux proteins, such as ATP-Binding Cassette (ABC) transporters localized on the Blood-Brain Barrier (BBB). The activity of ABC transporters seems to be a common mechanism that underlies the poor response of CNS diseases to therapies.
The molecular characterization of Breast Cancer Resistance Protein (BCRP/ABCG2), as an ABC transporter conferring multidrug resistance (MDR), has stimulated many studies to investigate its activity on the BBB, its involvement in physiology and CNS diseases and its role in limiting the delivery of drugs in CNS.
In this review, we highlight the activity and localization of BCRP on the BBB and the action that this efflux pump has on many conventional drugs or latest generation molecules used for the treatment of CNS tumors and other neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Iorio Lisa Anna, Ros da Martina, Fantappiè Ornella, Lucchesi Maurizio, Facchini Ludovica, Stival Alessia, Becciani Sabrina, Guidi Milena, Favre Claudio, Martino de Maurizio, Genitori Lorenzo and Sardi Iacopo, Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (7) . https://dx.doi.org/10.2174/1871520616666151120121928
DOI https://dx.doi.org/10.2174/1871520616666151120121928 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patents in Cancer Stem Cells
Recent Patents on Biomarkers Molecular Chaperone Hsp90 as a Target for Oxidant-Based Anticancer Therapies
Current Medicinal Chemistry Toward the Identification of Novel Carbonic Anhydrase XIV Inhibitors using 3D-QSAR Pharmacophore Model, Virtual Screening and Molecular Docking Study
Letters in Drug Design & Discovery Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Molecular Dynamics and Structural Studies of the Ets Domain-DNA Complexes
Current Bioinformatics Dexmedetomidine: A Novel Anesthetic Agent for Middle Ear Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Polymers Based on Phenyl Boric Acid in Tumor-Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Blocking the PI3K/PKB Pathway in Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents Potential Role of miRNA in Metastatic Cascade of Triple-Negative Breast Cancer
Current Cancer Drug Targets The Possible Existence of a Gut-Bone Axis Suggested by Studies of Genetically Manipulated Mouse Models?
Current Pharmaceutical Design Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Living Life to the Fullest: Early Integration of Palliative Care into the Lives of Children with Chronic Complex Conditions
Current Pediatric Reviews Subject Index To Volume 6
Current Molecular Medicine miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Antibodies Against Muscarinic Receptors in Breast Cancer: Agonizing Tumor Growth
Current Immunology Reviews (Discontinued) Promises and Challenges of Adult Stem Cells in Cancer Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents
Current Medicinal Chemistry SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Current Pharmaceutical Design G Protein-Coupled Receptors in Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets Repositioning of Difluorinated Propanediones as Inhibitors of Histone Methyltransferases and their Biological Evaluation in Human Leukemic Cell Lines
Anti-Cancer Agents in Medicinal Chemistry